Related Experiment Videos
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1
L M Smeaton1, V DeGruttola, G K Robbins
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, 651 Huntington Avenue, Francois-Xavier Bagnound Building, Boston, MA 02115-6017, USA. smeaton@sdac.harvard.edu
Controlled Clinical Trials
|April 18, 2001
Summary
This study compared initial antiretroviral therapy strategies for HIV-1. It found that using protease inhibitors and non-nucleoside reverse transcriptase inhibitors sequentially in three-drug regimens was effective for treatment-naïve patients.
Area of Science:
- Infectious Diseases
- Virology
- Clinical Trials
Background:
- HIV-1 infection requires effective antiretroviral therapy (ART).
- Optimizing initial ART regimens is crucial for long-term patient outcomes.
- Previous treatment strategies varied, necessitating comparative studies.
Purpose of the Study:
- To evaluate different initial antiretroviral treatment strategies for HIV-1.
- To compare four-drug versus sequential three-drug ART combinations.
- To determine optimal sequencing of protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Main Methods:
- Randomized, partially double-blinded, controlled trial (ACTG 384).
- 980 treatment-naïve HIV-1 infected subjects across 81 centers.
- Factorial design assessing drug combinations and sequences.
Main Results:
- The study addressed key questions regarding the optimal initial ART regimen.
- It compared four-drug versus sequential three-drug ART strategies.
- Investigated optimal sequencing of PIs, NNRTIs, and NRTI combinations.
Conclusions:
- The findings provide critical insights into effective initial ART for HIV-1.
- Results inform clinical decision-making for treatment-naïve individuals.
- The study design allowed for robust comparison of complex treatment strategies.